Nektar Therapeutics (0UNL.L) LSE

88.47

-6.0743(-6.42%)

Updated at April 23 07:14PM

Currency In USD

Key Executives

Name	Title	Pay	Year Born
Howard W. Robin	Chief Executive Officer, President & Director	2.17M	1953
Sandra A. Gardiner	Chief Financial Officer and Principal Financial & Accounting Officer	460,850	1966
Mark A. Wilson	Senior VP, Chief Legal Officer & Secretary	898,297	1972
Jonathan Zalevsky	Senior VP and Chief Research & Development Officer	1.15M	1975
Ken Franke	Senior Vice President of Biologics Process Development & Manufacturing	0	N/A
Mary Tagliaferri	Chief Medical Officer	0	1966
Jason Barnard	Chief Accounting Officer	0	N/A
Robert Bacci	Chief People Officer and Head of Quality & Facilities	0	N/A
Charleen Jue	Senior Vice President of Clinical Development Operations	0	N/A
Jennifer Ruddock	Chief Business Officer	0	N/A

Name

Title

Pay

Year Born

Howard W. Robin

Chief Executive Officer, President & Director

2.17M

1953

Sandra A. Gardiner

Chief Financial Officer and Principal Financial & Accounting Officer

460,850

1966

Mark A. Wilson

Senior VP, Chief Legal Officer & Secretary

898,297

1972

Jonathan Zalevsky

Senior VP and Chief Research & Development Officer

1.15M

1975

Ken Franke

Senior Vice President of Biologics Process Development & Manufacturing

N/A

Mary Tagliaferri

Chief Medical Officer

1966

Jason Barnard

Chief Accounting Officer

N/A

Robert Bacci

Chief People Officer and Head of Quality & Facilities

N/A

Charleen Jue

Senior Vice President of Clinical Development Operations

N/A

Jennifer Ruddock

Chief Business Officer

N/A

Description

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19. It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat solid tumors, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.